Clinical study for breast cancer prognosis combined protocol

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026041

Enrollment

Unknown

Registered

2019-09-19

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Experimental group:Treatment regimen was adjusted according to comprehensive prognostic evaluation

Control group:Standard treatment

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Luminal A/B type of stage I-II breast cancer; 2. Have a mastectomy; 3. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Other tumors; 2. Inappropriate blood drawing or unqualified blood sample quality; 3. Other circumstances that the doctor deems unsuitable to participate in the clinical trial.

Design outcomes

Primary

Measure	Time frame
recurrence;ctDNA;	—

Countries

China

Contacts

Public ContactGuoqing Wang

Beijing Capitalbio Medlab

gqwang@capitalbiotech.com+86 13810750991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026